APAZIQUONE,1H-INDOLE-4,7-DIONE, 5-(1-AZIRIDINYL)-3-(HYDROXYMETHYL)-2-(3-HYDROXY-1-PROPENYL)-1-METHYL-, (E)-

Apaziquone is a member of indoles.|Apaziquone has been investigated for the treatment of Bladder Cancer and Bladder Neoplasms.|Apaziquone is an indolequinone bioreductive prodrug and analog of mitomycin C with potential antineoplastic and radiosensitization activities. Apaziquone is converted to active metabolites in hypoxic cells by intracellular reductases, which are present in greater amounts in hypoxic tumor cells. The active metabolites alkylate DNA, resulting in apoptotic cell death. This agent displays selectivity activity towards both hypoxic solid tumors, which exhibits higher expression of cytochrome P450 reductase, and well-oxygenated malignant cells that overexpress the bioreductive enzyme NQO1 (NAD(P)H: quinone oxidoreductase). Apaziquone may selectively sensitize hypoxic tumor cells to radiocytotoxicity.

ChEBI: Apaziquone is a member of indoles.

Apaziquone is an indolequinone that is a bioreductive prodrug and a chemical analog of Mitomycin C (M371900), a chemotherapeutic agent. Apaziquone is a potential therapeutic agent for the treatment of non-muscle invasive bladder cancer.

Molecular Weight:288.30
XLogP3:-0.5
Hydrogen Bond Donor Count:2
Hydrogen Bond Acceptor Count:5
Rotatable Bond Count:4
Exact Mass:288.11100700
Monoisotopic Mass:288.11100700
Topological Polar Surface Area:82.5
Heavy Atom Count:21
Complexity:524
Defined Bond Stereocenter Count:1
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes